Last updated on August 2019

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Clinical Study Identifier: NCT03518086

Find a site near you

Start Over

Hopital Louis Mourier

Colombes Cedex, France
  Connect »

Hopital Beaujon

Clichy, France
2.68miles
  Connect »

Hopital Saint-Louis

Paris, France
6.37miles
  Connect »